Fibrosis in Chronic and Delayed Myocardial Infarction

NCT ID: NCT05756608

Last Updated: 2026-01-09

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 180 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-11-10
• Study Completion Date: 2028-08-31

Brief Summary

In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.

Detailed Description

The investigators aim to investigate the role of fibrosis activity using 68Ga-FAPI and 18F-AlF-FAPI PET in chronic and delayed valvular, myocardial and endocardial injury states, in particular aortic stenosis, chemotherapy induced cardiotoxicity and carcinoid heart disease. The investigators also aim to analyse serum markers of myocardial injury and fibrosis at different time-points in these patient cohorts.

Research Hypothesis

1. In patients with aortic stenosis, myocardial fibrosis activity will correlate with markers of left ventricular decompensation and aortic valve fibrosis activity, will predict progression in fibrosis burden and will decline following aortic valve replacement.

2. Increased myocardial fibrosis activity will be observed in the early stages of anthracycline- induced cardiotoxicity and will predict later deterioration in cardiac function.

3. In patients with carcinoid syndrome, increased endocardial fibrosis activity will be observed in patients with subclinical and clinically significant valve involvement.

Conditions

Aortic Stenosis; Chemotherapy Induced Systolic Dysfunction; Carcinoid Syndrome

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Aortic stenosis

The investigators will recruit 70 patients with aortic stenosis (25 patients with asymptomatic moderate aortic stenosis and 25 patients with symptomatic severe aortic stenosis, 10 patients with mild aortic stenosis and 10 patients with aortic sclerosis) and 10 healthy volunteers, who will undergo baseline 68Ga-FAPI or 18F-AlF-FAPI PET/MR imaging to establish fibrosis activity in healthy myocardium and in context of chronic myocardial injury. All patients will have a follow up FAPI PET/ MR scan 1 year after their baseline scan to assess whether myocardial fibrosis activity reverses following aortic valve replacement and restoration of normal afterload in patients with severe aortic stenosis and if baseline myocardial fibrosis activity can predict progression in the fibrosis burden and clinical progression in patients with mild or moderate aortic stenosis or aortic sclerosis. Healthy volunteers will not undergo any repeat imaging.

68Ga-FAPI and 18F-AlF-FAPI PET-MR

Intervention Type: DIAGNOSTIC_TEST

Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Chemotherapy-induced cardiotoxicity

The investigators will recruit 60 patients who have undergone anthracycline treatment \>1 year from enrollment and 10 healthy volunteers as part of this cohort. This will include 50 patients who have either clear evidence of cardiotoxicity (Ejection fraction \<50% and a 10%point fall in ejection fraction) or a subclinical cardiac injury (elevated troponin, elevated T2, impaired global longitudinal strain) and 10 patients with no evidence of cardiotoxicity on their cardiac MRI scan (performed as part of the ongoing Cardiac CARE study). These patients will undergo baseline FAPI PET/MR imaging to establish the extent and pattern of myocardial fibrosis activity in context of delayed myocardial injury (chemotherapy-induced cardiotoxicity). All patients will have a follow up cardiac MRI scan 1-2 years after their baseline scan to assess whether baseline fibrosis activity is associated with a deterioration in cardiac function. Healthy volunteers will not undergo any repeat imaging.

68Ga-FAPI and 18F-AlF-FAPI PET-MR

Intervention Type: DIAGNOSTIC_TEST

Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Carcinoid syndrome

In collaboration with the South East Scotland NET Service, the investigators will recruit 30 patients with carcinoid syndrome for this cohort. These patients will undergo a baseline echocardiogram and a FAPI PET/MR scan to investigate fibrosis activity within the cardiac chambers and valves. The investigators will recruit patients with established cardiac involvement as well as carcinoid syndrome patients with high circulating 5-HT concentrations who have no evidence of valve disease on echocardiography. All patients will have a follow up cardiac MRI scan and an echocardiogram, 6 months - 1 year after their baseline scan to assess whether baseline fibrosis activity is associated with subsequent deterioration in cardiac and valvular function.

68Ga-FAPI and 18F-AlF-FAPI PET-MR

Intervention Type: DIAGNOSTIC_TEST

Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Interventions

68Ga-FAPI and 18F-AlF-FAPI PET-MR

Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

Cohort 1(Aortic stenosis):

• Male or female above the age of 50 years old
• Provision of informed consent prior to any study specific procedures
• 25 patients with symptomatic severe aortic stenosis (peak velocity >4.0 m/s)
• 25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s)
• 10 patients with mild aortic stenosis (peak velocity 2.6-2.9 m/s)
• 10 patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow)
• 10 healthy volunteers (no other significant co-morbidities, as assessed by the study PI)

Cohort 2 (Chemotherapy-induced cardiotoxicity):

• Male or female over the age of 35 years with evidence of cardiotoxicity on cardiac MRI (performed as part of the Cardiac care study), at least 1 year after anthracycline treatment.
• 10 patients over the age of 35 years (male or females) without evidence of fibrosis on their 1-year scan after anthracycline treatment.
• 10 healthy volunteers (>35 years of age) with no significant co-morbidities, as assessed by the study PI.
• Provision of informed consent prior to any study specific procedures

Cohort 3 (Carcinoid syndrome):

• 30 patients with carcinoid syndrome (with or without cardiac involvement), over the age of 35 years, diagnosed as per consensus guidelines
• Provision of informed consent prior to any study specific procedures

Exclusion Criteria

• Inability or unwilling to give informed consent.
• History of claustrophobia or feeling of inability to tolerate supine position for the MRI scans.
• Impaired renal function with eGFR of <30 mL/min/1.73m2.
• Women who are pregnant or breastfeeding.
• Contrast allergy
• Contraindication to cardiac MRI (e.g. metallic implant or severe claustrophobia)
• Recent myocardial infarction, other known causes of cardiomyopathy/cardiac fibrosis.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Edinburgh

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marc Dweck, MBBS PhD

Role: STUDY_CHAIR

University of Edinburgh

Locations

University of Edinburgh

Edinburgh, Scotland, United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Krithika Loganath, MBBS

Role: CONTACT

kloganat@ed.ac.uk

07774365798

Facility Contacts

Krithika Loganath

Role: primary

kloganat@ed.ac.uk

07774365798

Other Identifiers

300754

Identifier Type: -

Identifier Source: org_study_id